Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Melanoma 688Lymphoma, T-Cell, Cutaneous 116Keratosis, Actinic 109Skin Neoplasms 99Carcinoma, Non-Small-Cell Lung 81Mycosis Fungoides 79Neoplasm Metastasis 78Neoplasms 75Sezary Syndrome 74Lymphoma, Non-Hodgkin 72Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Follicular 64Lymphoma, Large B-Cell, Diffuse 63Lymphoma, B-Cell, Marginal Zone 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Lymphoma, Mantle-Cell 59Uveal Melanoma 58Carcinoma, Renal Cell 58Carcinoma, Basal Cell 58Lymphoma, Large-Cell, Immunoblastic 56Hodgkin Disease 56Burkitt Lymphoma 55Lymphoma 52Lymphoma, Large-Cell, Anaplastic 50Waldenstrom Macroglobulinemia 44Multiple Myeloma 44Lymphoma, Extranodal NK-T-Cell 44Breast Neoplasms 44Immunoblastic Lymphadenopathy 43Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Erdheim-Chester Disease × Dermatologic × Clear all
NCT04198818 2024-07-19

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Haihe Biopharma Co., Ltd.

Phase 1/2 Terminated
37 enrolled 30 charts
DermatologicMyeloidThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡